title: PPARgamma is essential for protection against nonalcoholic steatohepatitis.
abstract: Peroxisome proliferator-activated receptor-gamma (PPARgamma) is a transcription factor that regulates lipid metabolism and inflammatory responses. Certain PPARgamma ligands improve nonalcoholic steatohepatitis (NASH). The role of PPARgamma itself in NASH remains poorly understood. The functional consequences of PPARgamma in the development of steatohepatitis through gene deficiency or gene overexpression of PPARgamma delivered by adenovirus (Ad-PPARgamma) were examined. Our results show that PPARgamma-deficient (PPARgamma(+/-)) mice fed the methionine- and choline-deficient (MCD) diet developed more severe steatohepatitis than wild-type mice, and were unaffected by PPARgamma ligand rosiglitazone. Overexpression of PPARgamma delivered by Ad-PPARgamma attenuated steatohepatitis. This effect was associated with redistribution of fatty acid from liver to adipose tissue by enhancing expression of fatty acid uptake genes (fatty acid binding protein-4 (aP2), fatty acid translocase (CD36), lipoprotein lipase (LPL) and fatty acid transport protein-1 (FATP-1)) and lipogenic genes (sterol regulatory element binding protein isoform-1 (SREBP-1) and stearoyl-CoA desaturase isoform-1 (SCD-1)) in adipose tissue and to a lesser extent in liver. The anti-steatohepatitis action of PPARgamma was also mediated via regulating adipokines through suppressing tumor necrosis factor-alpha (TNF-alpha) and interleukin-6 (IL-6) and inducing adiponectin. Moreover, PPARgamma activation suppressed hepatic lipoperoxide and reduced hepatic pro-inflammatory cytokines (TNF-alpha and IL-6) production. In conclusion, PPARgamma is an important endogenous regulator and potential therapeutic target for nutritional steatohepatitis.
authors.affiliation: Institute of Digestive Disease and Department of Medicine, Li Ka Shing Institute of Health Sciences, The Chinese University of Hong Kong, Hong Kong, China.
authors.forename: C W
authors.initials: CW
authors.lastname: Wu
authors.forename: E S H
authors.initials: ES
authors.lastname: Chu
authors.forename: C N Y
authors.initials: CN
authors.lastname: Lam
authors.forename: A S L
authors.initials: AS
authors.lastname: Cheng
authors.forename: C W
authors.initials: CW
authors.lastname: Lee
authors.forename: V W S
authors.initials: VW
authors.lastname: Wong
authors.forename: J J Y
authors.initials: JJ
authors.lastname: Sung
authors.forename: J
authors.initials: J
authors.lastname: Yu
mesh_terms: D000256:Adenoviridae / Q000235:genetics; D000818:Animals; D002796:Choline Deficiency; D005234:Fatty Liver / Q000209:etiology / Q000235:genetics / Q000517:prevention & control*; D018014:Gene Transfer Techniques; D015316:Genetic Therapy; D008715:Methionine / Q000172:deficiency; D051379:Mice; D047495:PPAR gamma / Q000172:deficiency / Q000235:genetics / Q000378:metabolism*; D000077154:Rosiglitazone; D045162:Thiazolidinediones / Q000494:pharmacology
chemical_list: D047495:PPAR gamma; D045162:Thiazolidinediones; D000077154:Rosiglitazone; D008715:Methionine